REFERENCES

1. World Health Organization. WHO monographs on selected medicinal plants (volume 1). Geneva: WHO Publications; 1999. p. 1-4.
2. World Health Organization. Guideline for the appropriate use of herbal medicines. Manila: WHO Publications; 1998. p. 1-15.
3. Newell CA, Anderson LA, Phillipson JD. Herbal medicines, a guide for health-care professionals. London: The Pharmaceutical Press; 1996. p. 1-12.
4. Subeharoen P. Present status of traditional medicine in Thailand. In: International seminar on value and utilization of traditional medicine in health development. Bangkok: Queen Sirikit National Convention Center; 1995. p. 293-302.
5. Lewis DA. Anti-inflammatory drugs from plant and marine sources. Birmingham B4 7ET: England; 1989.
6. Rampasath VR, Shanthi P, Sachdanandam P. Anti-inflammatory effect of *Semecarpus ancardium* Linn. nut extract in acute and chronic inflammatory conditions. Biol Pharm Bull 2004;27:2028-31.
7. Kumara NKVMR. Identification of strategies to improve research on medicinal plants used in Sri Lanka. In: WHO symposium. University of Ruhuna: Sri Lanka; 2001.
8. Kassuya CAL, Aline S, Menezes-de-lima JO, Marotta DM, Rehder VLG, Calixto JB. Antiinflammatory and anti-allodynic action of the lignan niranthin isolated from *Phyllanthus amarus*, evidence for interaction with platelet activating factor receptor. Eur J Pharmacol 2006;546:182-8.
9. Gunatillake SN. In: Osuturu3. Sri Lanka: Department of Ayerveda; 1994. p. 144-9.
10. Kou J, Si M, Dai G, Lin Y, Zhu D. Anti-inflammatory activity of *Polygala japonica* extract. Fitoterapia 2006;77:411-5

11. El-Sayed NH, EI-Eaky W, Ibahim MT, Mabry TJ. Anti-inflammatory and ulcerogenic activities of *Salvia Triloba* extracts. Fitoterapia 2006;77:333-5.
12. Lawpattarakasem P, Hougton PJ, Hoult JRS, Itharat A. An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol 2003;85:207-15.
13. Salerno E. Overview of infection, inflammation and fever. In: Pharmacology for health. professional. St. Louis: Mosby; 1999. p. 640.
14. Hansen M. Inflammatory, immunity and related disorders. In: Pathophysiology foundation of disease and clinical intervention. Philadelphia: WB Saunders Company; 1998. p. 268-85.
15. Dale MM, Foreman JC. Introduction to the immunology and pathology of host defence mechanisms. In: Dale MM, Foreman JC, editors. Textbook of immunopharmacology. 2nd ed. London: Blackwell Scientific Publications; 1989. p. 2.
16. Page C, Curtis M, Walker M, Hoffman B. Drugs and the inflammatory and immune response. In: Integrated pharmacology. 2nd ed. Philadelphia: Mosby Internationl; 2002. p. 327-41.
17. Inflammation. [online] Available from: URL: http://en. Wikipedepia. org/ wikipedia.org/wiki/inflammatory (11 May 2007).
18. Fantone JC, Ward PA. Inflammation. In: Rubin E, Farber JL, editors. Pathology. 3rd ed. Philadelphia: Lippincott; 1999. p. 36-75.
19. Bryan J. Inflammation. In: Bullock BA, Henze RL, editors. Focus on pathophysiology. Philadelphia: Lippincott; 2000. p. 253-61.
20. Katzung BG, Furst DE. Nonsteroidal anti-inflammatory drugs; disease-modifying antirheumatic drugs; nonopioid analgesies; drugs in gout. In: Katzung BG, editor. Basic and Clinical Pharmacology. 8th ed. New York: McGraw-Hill Co; 2001. p. 578-600.
21. Rang HP, Dale MM, Ritter JM, Moore PK. Locol hormones inflammation and immune reactions. In: Pharmacology. 5th ed. Loanhead: Elsevier Science Limited; 2003. p. 219-42.

22. Mitchell RN, Cotran RS. Acute and Chronic inflammatory. In; Kumar V,Cotran RS, Robbin SL, editors. Robbins basic pathology. 7th ed. Philadelphia: WB Saunders; 2003. p. 33.
23. Collins T. Acute and chronic inflammation. In: Catran RS, Kumar V, Collins T, editors. Robbins pathologic basis of disease. 6th ed. Philadelphia: WB Saunders; 1999. p. 50-88.
24. Ranlein JA. Biological mediators of acute inflammation. CN Clin Issues 2004; 15(1):3-17.
25. Brow E. Inflammation Part two. In: Gilbert HF, editor. Basic concepts in pathology: a students survival guide. New York: McGraw-Hill; 1998. p. 206-8.
26. Murphy HS. Inflammation. In: Rubin R, Strayer DS, editors. Rubin's Pathology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 64-7.
27. Dale HH, Laidlaw PP. Further observations on the action of β-iminazolylethy-lamine. J Physiol 1919;43:182-95.
28. Vane JR. Prostaglandins in the inflammatory response. In: Lepow IH, Warol PA, editors. Inflammation: Mechanism and control. New York: Academic press; 1972. p. 261-79.
29. Hill SJ. Distribution, properties and functional characteristics of three classes of histamine receptors. Pharmacol Rev 1990;42(1):45-83.
30. Gantz I, Schaffer M, Delvalle J, et al. Molecutar cloning of a gene encoding the histamine H_2 receptor. Proc Natl Acad Sci USA 1991;88(2):429-33.
31. Liu C, Jiang MX, et al. Cloning and pharmacological characterization of a fourth hid mine receptor (H_4) expressed in bone marrow. Mol Pharmacol 2001; 59(3):420-6.
32. Morse KL, Behan J, Laz TM, et al. Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 2001;296(3):1058-66.
33. Alguacil LF, Perez-Garcia C. Histamine H_3 receptor: a potential drug target for the treatment of central nervous system disorders. Curr Drug Targets CNS Neurol Disord 2003;2(5):303-13.
34. Repka-Ramirez MS. New concepts of histamine receptors and actions. Curr Allergy Asthma Rep 2003;3(3):227-31.

35. Fung-Loung WP, Thurmond RL, Ling P, Karlsson L. Histamine H_4 receptor antagonists: the new antihistamines. Curr Opin Investig Drugs 2004;5(11): 1174-83.

36. Hancock AA, Brune ME. Assessment of pharmacology and potential anti-obesity properties of H_3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 2005;14(3):223-41.

37. Owen DAA. Inflammation, histamine and 5-hydroxytryptamine. Br Med Bull 1987;43(2):256-69.

38. Katzung BG, Julius DJ. Histamine, serotonin, and the ergot alkaloids. In: Katzung BG; editor: Basic and clinical pharmacology. 8th ed. New York: McGraw-Hill Co; 2001. p.265-29.

39. Gruber BL. Basophils, mast cells, and eosinophils. In: Sigal LH, Ron y, editors. Immunology and inflammation: basic mechanisms and clinical consequences. New York: McGraw-Hill; 1994. p. 347.

40. Stevens A, Lowe J. Tissue responses to damage. In: Pathology. 2nd ed. London: Harcourt Publishers Ltd; 2000. p. 35-9.

41. Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (Serotomin): receptor agonists and antagonists. In: Hardman JG, Limbird Le, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p.269-90.

42. Rack K, Schworer H. Regulation of serotonin release from the intestinal mucosa. Pharmacol Res 1991;23(1):13-25.

43. Racke K, Reimann A, Schworen H, Kilbinger H. Regulation of 5-HT release from enterochromaffin cells. Behave Brain Res 1996;73(1-2):83-7.

44. Sommer C. Serotomin in pain and and analgesia: actions in the periphery. Mol Neurobiol 2004;30(2):117-25.

45. Rang HP, Dale MM, Ritter JM. Other peripheral mediators: 5-hydroxytryptamine and purines. 3rd ed. London: Churchill Livingstone; 1995. p. 177-90.

46. O'Connor TM, O Connell J, O'Brien DL, et al. The role of substance P in inflammatory disease. J Cell Physiol 2004;201(2):167-80.

47. Suzuki H. Tachykininergic neurotransmission in the central nervous system. J Nippon Med She 2002;69(4):322-7.
48. Foegh ML, Ramwell PW. The Eicosanoids: Prostaglandins, thromboxanes, leukotrienes, and related compounds. In: Kataung BG, editor. Basic and clinical pharmacology. San Francisco: McGraw-Hill Companies; 2001. p. 314-15.
49. Regoli D. Kinins. Br Med Bull 1987;43(2):256-69.
50. Reid IA. Vasoactive peptides. In: Katzung BG, editor. Basic and clinical pharmacology. 8th ed. New York: Mc Graw-Hill; 2009. p. 292-325.
51. Cunning KM, Wagner E, Frank MM. Complement and kinin. In: Parslow TG, Stites DP, Terr AL, Imboden JB, editors. Medical immunology. 10th ed. New York: McGraw-Hill Companies; 2001. p. 175-88.
52. Brown NJ, Roberts LJ. Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE, editors. Goodman and Gilaman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Companies; 2001. p. 218-315.
53. Mackay IR, Rosen FS. Complement. N Engl J Med 2001;344(14):1058-66.
54. Complement system. [online]. Available http://en.wikipedia.org/wiki/ Complement_system (29 August 2007).
55. Mongar JL. Complement. In: Dale MM, Foreman JC, editors. Text book of Immunopharmacology 2nd ed. London: Blackwell Scientific; 1989. p. 149-56.
56. Male D. Complement. In: Roitt I, Brostoff J, Male D, editors: Immunology. 6th ed. London; 2001. p. 54-60.
57. Morrow JD, Roberts IILJ. Eicosanoids and platelet-activation factor. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutic. 10th ed. New York: McGraw-Hill Companies; 2001. p. 669-80.
58. Roberts LJ, Morrow JD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. London: McGraw- Hill; 2001. p. 687-731.

59. Abe M, Oka T, Hori T, Takahashi S. Prostanoids in the preoptic hypothalamus mediate systemic lipopysaccharid-induced hyperalgesia in rats. Brain Res 2001; 916(1-2);41-9.

60. Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997;121(30):579-87.

61. Furst DE, Hillson J. Aspirin and other nonsteroidol anti-inflammatory drugs. In: Koopman WJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 665-716.

62. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005; 12(1):46-55.

63. Chandrasekharan NV, Dai H, Roos KL, Evanson Nk, Tomsik J, Eltom TS, Simmon DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2000;99:13926-31.

64. Kontogiorgis CA, Hadjipavlou-Litina DJ. Nonsteroidal anti-inflammatory and anti-allergy agents. Curr Med Chem 2002;9(1):89-98.

65. Furst DE, Ulrich RW. Nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, nonopioid analgesics, 4 durgs used in gout. In: Katzung BG, editor. Basic and clinical pharmacology. 10th ed. New York: McGraw-Hill, 2007. p. 578.

66. Gould BE. Inflammation and healing. In: Pathophysiology for the health professions 2nd ed. Philadelphia: WB Saunders Company; 2002. p. 12-33.

67. Davies NM, SAleh JY, Skjodt NM. Detection and prevention of NSAIDs-induced enteropathy. J Pharm Pharm Sci 2003;(1):137-55.

68. Wallelr DG, Renwick AG, Hillier K. Non-steroidal anti-inflammatory drugs. In: Medical pharmacology and therapeutics. 1st ed. Spain: Harcourt Publishers Ltd, 2001. p. 305-14.

69. Coppelli G, Guaita E, Spaggiari S, Coruzzi G. Gastric effect of the selective cyclooxygenase-2 inhibitor, celecoxib in the rat. Dig Liver Dis 2004;36:265-70.

70. Bley KR, Hunter JC, Eglen RM, Smith JAM. The role of IP prostanoid receptor in inflammatory pain. Trends Pharmacol Sci 1998;19:141-7.
71. Masferer JL, Zweiofel BS, Manning PT. Selective inhibition of inducible cylooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
72. Ganong WF. Endocrinology, metabolism & reproductive function: energy balance, metabolism & nutrition. In: Review of medical physiology. 2th ed. New York: McGraw-Hill Co; 2001. p. 299-300
73. Abrams AC. Narcotic analyesics and narcotic antagonists. In: Clinical drug therapy rationales for nursing practice. 5th ed. Philadelphia: Lippincott; 1988. p. 62-80.
74. Sackett K, Cannon CA. Pain. In: Bullock BA, Itenze RL, editors. Focus on Pathophysiology. Philadelphia: Lippincott; 2000. p. 1047-9.
75. Insel PA. Analgesic-antipyretics and anti-inflarmmatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. Singapore: Pergamon Press; 1991. p. 639-41.
76. Byer VL. Drugs that provide pain relief. In: Kuhn MM, editor. A pharmacotherapeutics. A nursing process approach. 2nd ed. Philadelphia: P.A. Davis; 1991. p. 451-93.
77. Fever [online] Available from: URL: http://en.wikipedia.org/wiki/. Thermoregulation. (20 May 2007).
78. Dascombe MJ. The pharmacology of fever. Prog Neurobiol 1985; 25(4): 327-73.
79. Salerno E. Overview of infections, inflammation, and fever. In: Pharmacology for Health professionals. St. Louis: Mosby; 1999. p. 642.
80. Milton AS. Prostaglandins and fever. TIPS 1982;40:490-2.
81. Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 1962;11:544-7.

82. Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther 1969;16(1):96-103.

83. Di Rosa M. Biological properties of carrageenan. J Pharm Pharmacol 1972; 24(2):89-102.

84. Di Rosa M, Ground JP, Willoughby DA. Studies of the acute inflammatory response induced in rat in different sites by carrageenan and turpentine. J Pathol 1971;104:15-29.

85. Sedgwick AD, Willoughby DA. Animal models for testing drugs on inflammatory and hypersensitivityreactions. In: Dale MM, Foreman JC, editors. Textbook of immunology. 2nd ed. Oxford: Blackwell Scientific;1989: 253-61.

86. Peck MJ, Piper PJ, Williums TJ. The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins 1981;21:315-21.

87. DiMartino MJ, Campbell GK, Wolff CE, Hanna N. The pharmacology of arachidonic acid induced rat paw edema. Agents Actions 1987;21(3-4):303-5.

88. Swingle KF, Shideman FE. Phases of the inflammatory response to subcutaneous implantation of cotton pellet and their modification by certain anti-inflammatory agents. J Pharmacol Exp Ther 1972;183(1):226-34.

89. Firkin F, Chesterman C, Penington D, Fush G. White cells: neutrophilia and eosinophilia; neutropenia and agranulocytosis; infectious mononucleosis. In: de Gruchy's Clinical heamatology in medical practice. 5th ed. Australia: Blackwell Scientific; 1989. p. 216-35.

90. Nishikjaze O, Takita H, Takase T. Activity of newly discovered protease in carrageenin-induced inflammation in rats. IRC Medical science, biochemisty, connective tissue; skin and bune; surver and transplantation 1980;8:725.

91. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgasic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1979;4:161-74.

92. Noble F, Smadja C, Valverde O, Maldonado R, Coric P, Turcaud S, Zaluski MCF, Roques BP. Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin metabolizing enzyme inhibitor RB 120. Pain 1997;73:383-91.

93. Hunskaar S, Fasmer OB, Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Meth 1985;14:69-76.

94. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987;30(1):103-14.

95. Shibata M, Ohkubu T, Takahashi H, Inoki R. Modified formalin test: Characteristic biphasic pain response. Pain 1989;38:347-52.

96. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992;51(1):5-17.

97. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol 1972; 22(4):672-5.

98. Ganong WF. Functions of the nervous system: central regulation of visceral function. In: Ganong WF, editor. Review of medical physiology. 20th ed. New York: McGraw-Hill; 2001. p. 245-7.

99. เต็ม สมิตินันทน์. ชื่อพรรณไม้แห่งประเทศไทย 6 ชื่อ พฤกษศาสตร์ชื่อพื้นเมือง. กรุงเทพฯ: สำนักวิชาการป่าไม้ กรมป่าไม้; 2543.

100. ฐานข้อมูลสถาบันรุกขเวช“โปร่งกิ่ว”[online] Abailable from: URL: http://walai.msu.ac.th. Link http://202.28.32.25/cdb/quicksearch.asp (20 May 2006).

101. ฐานข้อมูลด้านการเกษตร เครือข่ายสารสนเทศเกษตรไทย “ข้อมูลพรรณไม้-โปร่งกิ่ว” [online]. Available from: URL: http://aqkc.lib.ac.th/plantinfo.php?code=195link pdf/195pdf (20 May 2006).

102. นพมาศ สุนทราเจริญนนท์, อนุชา บุญจรัส, รุ่งระวี เต็มศิริฤกษ์กุล, อาทร วิ่งไพบูลย์. กกยา อีสาน. กรุงเทพ; มูลนิธิมหาวิทยาลัยมหิดล; 2543.

103. Leboeof M, Cave A, Bhaumik PK, Mukherjee B, Mukherjee R. The photochemistry of the Annonaceae. Photochemistry 1982;21(12):2783-813.

104. Sinz A, Matusch R, Kampchen T, Fiedler W, Schmidt J, Santisuk T, Wangcharoentakul S, Chaichana S, Reutrakul V. Novel acetogenins from the

leaves of *Dasymaschalon scootpense*. J Helvetica Chimica Acta 1998;81:1608-15.

105. Bessey OA, Lowry OH, Brock MJ. Method for the determination of alkaline phosphatase with five cubic millimeters of serum. J Biol Chem 1946;164:321-9.
106. Milano F, Serrano JS, Pascual J, Sancibrain M. Effect of GABA on gastric acid secretion and ulcer formation in rats. Life Sci 1987;41(13):1651-8.
107. Teotino U, Friz LP, Gandini A, Dellabella D. Thio derivatives of 2,3-dihydro-4H-1,3-benzoxazin-4-one synthesis and pharmacological properties. J Med Chem 1963;55:248-50.
108. Buyukokuroglu ME. Anti-inflammatory and antinociceptive properties of dantrlene sodium in rats and mice. Pharmacol Res 2002;45(6):456-60.
109. Rang HP, Dale MM, Ritter JM, Moore PK. Anti-inflammatory and immunosuppressant drugs. In: Pharmacology. 5th ed. Loanhead: Elsevier Science Limited; 2003. p. 244-6.
110. Derle DV, Gujar KN, Sagar BSH. Adverse effects associated with the use of nonsteroidal anti-inflammatory drug: An overview. Indian Jurnal of Pharm Sci 2006;409-14.
111. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
112. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004;364:639-40.
113. Berenbaum F. Selective cyclooxygenase-2 inhibitors: hope and facts. Joint Bone Spine 2000;67:499-501.
114. Berenbaum F. Vioxx and cardiovascular events: a class effect. Joint Bone Spine 2005;72:1-3.
115. Araico A, Terencio MC, Alcaraz MJ, Domíguez, JN, León C, Ferrándiz ML. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual

cyclo-oxygenase-2/5-lipoxygenase inhibitor Life Sci2007;doi: 10.1016/j.lfs. 2007.03.017.

116. Handy RLC, More PK. Acomparison of the effect of 1-NAME,7-NI and L-NIL on carageenan-induced hind paw oedema and NOS activity. Br J Pharmacol 1998; 123:1083-8.
117. Miller MUS, Grisham MB. Nitric oxide as a mediator of inflammation, you had better believed it. Mediat.Inflamm.1995;4:387-96.
118. Salvemini d, Wang ZQ, Wyatt PA, Bourdon DM, Marino MH, Manning PT, Currie MG. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 1996;188:829-38.
119. Ueno A, naraba H, Ikeda Y, et al. Intrinsic prostacyclin contributes to exudation induced by bradykinin or carrageenin: a study on the paw edema induced in IP-receptor_deficient mice. Life Sci 2000; 66(12):p. 55-60.
120. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002; 9: 1033-43.
121. Suleyman H, Yildirim D, Aslan A, et al. An investigation of the anti-inflammatory effects of an extract from *Cladonia rangiformis* HOFFM. Biol Pharm Bull 2002;25(1):10-3.
122. Cooper NR. Biology of the Complement System. In: Inflammation: Basic principles and clinical correlates 3 rd ed. Philadelphia: Lippincott Williams and Wilkins; 199. p. 218-315.
123. Giuliano F, Warner TD. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol 1999;126:1824-30.
124. Ismail TS, Gopalakrishnan S, Begum VH, Elango V. Anti-inflammatory activity of *Salacia oblonga* Wall. and *Azima tetracantha* Lam. J Ethnopharmacol 1997;56(2):145-52.
125. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Bio Sci 2004;9:283-9.
126. Olajide OA, Awe SO, Makinde JM, Ekhelar AI, Olusola A, Morebise O, Okpako DT. Studies on the anti-inflammatory, antipyretic and analgesic properties of the *Alstonia boonei* stem bark. J Ethnopharmacol 2000;71:179-86.

127. Olajide OA, Makinde JM, Awe SO. Effect of the aqueous extract of *Bridelia ferruginea* stem bark on carrageenan-induced edema and granuloma tissue formation in rats and mice. J Ethnopharmacol 1999;66:113-7.
128. Bailey PJ, Sturm A, Lopez-Ramos B. A biochemical study of the cotton pellet granuloma in the rat. Effects of dexamethasone and indomethacin. Biochem Pharmacol 1982; 31(7):1213-8.
129. Whiteley PJ, Needleman P. Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor. J Clin Invest 1984;74(6): 2249-53.
130. Berne RM, Levy MN. The adrenal glands. In: Physiology. St. Louis Missouri: Mosby-year book;1998. p. 930-50.
131. Suleyman H, Yildirim D, Aslan A, Göçer F, Gepdiremen A, Güvenalp Z. An investigation of the anti-inflammatory effects of an extract from *Cladonia rangiformis* Hoffm. Biol Pharm Bull 2002;25(1):10-3.
132. Arrigoni-Martellie E. Inflammation and anti-inflammation. Spectrum Publication: New York; 1977. p. 119-20.
133. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull 1987; 43(2): 285-96.
134. Naik SR, Sheth UK. Studies on two new derivatives of N-aralkyl-o-ethoxybenzamides: Part II--biochemical studies on their anti-inflammatory activity. Indian J Exp Biol 1978;16(11):1175-9.
135. Rainsford KD. Agents Actions. 1993;39:24.
136. Boyd JR. Drug facts and comparison. Missousi: JB Lippincott, 1982: 33-9.
137. Analgesic antipyretic anti-inflammatory & related drugs. [online]. Available from: URL: http://quark.qmc.ufsc.br/qmcweb/artigos/dor/bonus/pain_killers (29August 2000).
138. Beaugerie L, Thiefin G. Gastrointestinal complications related to NSAIDs. Gastroenterol Clin Biol 2004;28:62-72.
139. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001;41(4):299-332.
140. Rosland JH, Tjolsen A, Maehle B, Hole K. The formalin test in mice: effect of formalin concentration. Pain 1990;42(2):235-42.

141. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1 beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410(6827):471-5.
142. Seybold VS, Jia YP, Abrahams LG. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain 2003;105(1-2):47-55.
143. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390(2):165-9.
144. Rivot JP, Montagne-Clavel J, Besson JM. Subcutaneous formalin and intraplantar carrageenan increase nitric oxide release as measured by in vivo voltammetry in the spinal cord. Eur J Pain 2002;6(1):25-34.